LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

3.61 0.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.5300000000000002

Max

3.77

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
EPS	-0.503
Darbinieki	106
EBITDA	-619K -38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+91.26% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-11M 283M
Iepriekšējā atvēršanas cena	3.05
Iepriekšējā slēgšanas cena	3.61

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. jūn. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

2026. g. 8. jūn. 15:41 UTC

Galvenie tirgus virzītāji

American Battery Shares Jump on Energy Department Victory

2026. g. 8. jūn. 23:46 UTC

Tirgus saruna

Nikkei May Rebound After Monday's Selloff -- Market Talk

2026. g. 8. jūn. 23:37 UTC

Tirgus saruna

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

2026. g. 8. jūn. 23:25 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 21:57 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

2026. g. 8. jūn. 21:56 UTC

Iegādes, apvienošanās, pārņemšana

Salesforce Agrees to Buy m3ter

2026. g. 8. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 8. jūn. 19:22 UTC

Tirgus saruna

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

2026. g. 8. jūn. 19:01 UTC

Tirgus saruna

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 8. jūn. 18:52 UTC

Tirgus saruna

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

2026. g. 8. jūn. 18:17 UTC

Tirgus saruna

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

2026. g. 8. jūn. 17:32 UTC

Tirgus saruna

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

2026. g. 8. jūn. 17:29 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 8. jūn. 16:55 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

2026. g. 8. jūn. 16:54 UTC

Iegādes, apvienošanās, pārņemšana

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

2026. g. 8. jūn. 16:40 UTC

Tirgus saruna

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 16:31 UTC

Tirgus saruna

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

2026. g. 8. jūn. 16:27 UTC

Tirgus saruna

Mexican Inflation Seen Easing in May -- Market Talk

2026. g. 8. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 8. jūn. 16:03 UTC

Iegādes, apvienošanās, pārņemšana

Orange Bought Stake From Lorca

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

2026. g. 8. jūn. 16:01 UTC

Iegādes, apvienošanās, pārņemšana

Orange Acquires 100% Ownership of MasOrange

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 8. jūn. 15:58 UTC

Tirgus saruna

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

2026. g. 8. jūn. 15:55 UTC

Tirgus saruna

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

2026. g. 8. jūn. 15:41 UTC

Tirgus saruna

Gold Falls Below 200-Day Moving Average -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

91.26% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 91.26%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.